期刊文献+

缬沙坦治疗慢性肾小球肾炎合并高血压患者的临床效果分析 被引量:7

Clinical analysis of vaisartan in the treatment of chronic glomerulonephritis complicated with hypertension
下载PDF
导出
摘要 目的分析用缬沙坦治疗慢性肾小球肾炎合并高血压的临床效果。方法选取88例慢性肾小球肾炎合并高血压患者随机分为对照组(44例)和试验组(44例)。试验组给予缬沙坦分散片治疗,对照组给予盐酸贝那普利片治疗,对比分析两组患者的临床疗效。结果在对照组患者治疗的总有效率为61.36%。试验组患者治疗的总有效率为88.64%。试验组患者治疗的总有效率明显高于对照组患者,差异显著(P〈0.05),有统计学意义。结论为慢性肾小球肾炎合并高血压患者应用缬沙坦进行治疗可取得理想的效果,此法值得在临床上推广应用。 Objective To analyze the clinical effect of valsartan in the treatment of chronic glomerulonephritis complicated withhypertension. Methods 88 patients with chronic glomerulonephritis complicated with hypertension were randomly divided into con trol group(n=44) and experimental group(n=44). Benazepril Hydrochloride Tablets treatment, compared the clinical efficacy of the two groups. Results The total effective rate was 61.36 % in the control group, the difference was significant(P〈0.05) ,which was statistically significant. Conclusion The application of valsartan in the treatment of patients with chronic glomerulonephritis and hypertension can achieve an ideal effect,which is worthy of clinical application.
作者 胥智勇 敬莉蓉 杜华 XU Zhi-yong JING Li-rong DU Hua(Shehong People's Hospital, Sichuan 629200,Chin)
出处 《检验医学与临床》 CAS 2017年第A01期159-161,共3页 Laboratory Medicine and Clinic
关键词 缬沙坦 高血压 慢性肾小球肾炎 疗效 valsartan hypertension chronic glomerulonephritis effect
  • 相关文献

参考文献12

二级参考文献68

  • 1王玉,李晓玫.慢性肾脏病与高血压相关研究的热点问题[J].中国实用内科杂志,2007,27(10):814-818. 被引量:16
  • 2侯凡凡,谢迪.慢性肾脏病的治疗——合理降压控制尿蛋白逆转肾小球硬化[J].中国实用内科杂志,2007,27(13):1010-1012. 被引量:29
  • 3Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy[J].Kidney Int,2000,57 ( 2 ): 601-606.
  • 4Sasaki K, Anderson E, Shankland SJ, et al. Diffuse proliferative glomerulonephritis associated with eetuximab, an epidermal growth factor receptor inhibitor[ J ]. Am J Kidney Dis, 2013 ;61:988 - 991.
  • 5Shvetsov MIu, Medvedeva Tlu, Kozlovskaia NL, et al. Experience in the use of valsartan with the aim to inhibit progression of kidneyfail- ure(BIS) in patients with chronic glomerulonephritis[ J]. Ter Arkh, 2001 ;73:55 -61,.
  • 6Gu C, Zhou G, Noble NA, et al. Targeting reduction of proteinuria in glomerulonephritis: Maximizing theantifibrotic effect of valsartan by protecting podocytes [ J ]. J Renin Angiotensin Aldosterone Syst, 2012;9:415 -419.
  • 7Podrackd L, Matoussovic K. Practice guideline and trends for immu- nosuppressive treatment of glomemlonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis) [ J]. Vnitr Lek, 2013 ;59:113 - 118.
  • 8Schaefer F, Coppo R, Bagga A, et al. Efficacy and safety of valsar- tan in hypertensive children 6 months to 5 years of age[J]. J Hyper- tens, 2013 ;31:993 - 1000.
  • 9Macdonald K, Bri~ H, Vancayzeele S, et al. Modelling of blood pressure outcomes in patients with and without cular or renal disease following treatment with valsartan ( the PRE- VIEWstudy) [J].Arch Cardiovasc Dis, 2013 ; 106 : 124 - 134.
  • 10王远英,孙承美.ARB的肾保护作用机制和临床应用研究进展[J].中国医药导报,2007,4(12S):27-28. 被引量:15

共引文献138

同被引文献77

引证文献7

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部